A Covid vaccine compensation scheme could be set up after thousands claimed they have been left disabled as a result of the AstraZeneca jab, The Telegraph has learnt. The Health Secretary is ...

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

Before joining BeiGene, Yin spent 15 years with AstraZeneca, having served in various posts at the British drugmaker, including as head of its oncology business in China. Yin has been detained by ...

Their research suggested that neoadjuvant therapy with a combination of ribociclib and letrozole could be an alternative to multi-drug neoadjuvant chemotherapy. The trial involved high risk ...

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment ...

NEW YORK – The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) on Friday said it would recommend marketing authorization for Novartis' CDK4/6 inhibitor Kisqali ...

(IN BRIEF) AstraZeneca presented significant advancements in the prevention of infectious diseases at IDWeek 2024, showcasing its dedication to addressing respiratory infections caused by RSV, hMPV, ...

FluMist is an efficacious and safely tolerated intranasal influenza vaccine. FluMist has gained approval from the FDA for self-administration by patients aged 18-49. FluMist is the first influenza ...

This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the ...

In an interview with China Daily, Sharon Barr, executive vice-president of biopharmaceuticals R&D at AstraZeneca, said the company's presence in Shanghai is absolutely critical to achieving its ...

NEW YORK – AstraZeneca and Daiichi Sankyo's filing last week seeking approval for Enhertu (trastuzumab deruxtecan) in HER2-low and -ultralow hormone receptor (HR)-positive advanced breast cancer ...